Fiche publication
Date publication
février 2018
Journal
Oncotarget
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie
,
Pr GHIRINGHELLI François
,
Dr VINCENT Julie
,
Dr BENGRINE-LEFEVRE Leila
,
Dr FUMET Jean-David
Tous les auteurs :
Fumet JD, Bertaut A, Bengrine L, Lapierre P, Vincent J, Ghiringhelli F, Falvo N
Lien Pubmed
Résumé
Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density. We evaluated the link between decreased capillary density and the response to bevacizumab-based chemotherapy.
Mots clés
angiogenesis, bevacizumab, capillary rarefaction, colorectal cancer
Référence
Oncotarget. 2018 Feb 27;9(16):12599-12608
